Shen (Kidney)-tonifying principle for primary osteoporosis: to treat both the disease and the Chinese medicine syndrome

Bing Shu; Qi Shi; Yong-jun Wang

doi:10.1007/s11655-015-2306-z

Your Location：

Home >

Browse articles >

Shen (Kidney)-tonifying principle for primary osteoporosis: to treat both the disease and the Chinese medicine syndrome

OriginalPaper | Updated：2021-08-27

- Shen (Kidney)-tonifying principle for primary osteoporosis: to treat both the disease and the Chinese medicine syndrome
- Shen (Kidney)-tonifying principle for primary osteoporosis: to treat both the disease and the Chinese medicine syndrome
- 中国结合医学杂志（英文版） 2015年21卷第9期页码：656-661
- Affiliations：
  
  1. Longhua Hospital, Shanghai University of Traditional Chinese Medicine,Shanghai,China
  2. Spine Research Institute, Shanghai University of Traditional Chinese Medicine,Shanghai,China
- Author bio：
- Funds：
  
  Supported by the National Basic Research Program of China (973 Program, No. 2010CB530400), the Program for Innovative Research Team in University (No, IRT1270), National Natural Science Foundation of China (No. 81403239), Shanghai Natural Science Foundation (No. 12ZR1450400), and 085 Project of Shanghai University of Traditional Chinese Medicine (No. 085ZY1204)
- DOI：10.1007/s11655-015-2306-z
  中图分类号：
- 纸质出版日期：2015，
  
  网络出版日期：2015-10-3，
Scan for full text
Shu, B., Shi, Q. & Wang, Yj. Shen (Kidney)-tonifying principle for primary osteoporosis: to treat both the disease and the Chinese medicine syndrome., Chin. J. Integr. Med. 21, 656–661 (2015). https://doi.org/10.1007/s11655-015-2306-z

Bing Shu, Qi Shi, Yong-jun Wang. Shen (Kidney)-tonifying principle for primary osteoporosis: to treat both the disease and the Chinese medicine syndrome[J]. Chinese Journal of Integrative Medicine, 2015,21(9):656-661.
Shu, B., Shi, Q. & Wang, Yj. Shen (Kidney)-tonifying principle for primary osteoporosis: to treat both the disease and the Chinese medicine syndrome., Chin. J. Integr. Med. 21, 656–661 (2015). https://doi.org/10.1007/s11655-015-2306-z DOI：

Bing Shu, Qi Shi, Yong-jun Wang. Shen (Kidney)-tonifying principle for primary osteoporosis: to treat both the disease and the Chinese medicine syndrome[J]. Chinese Journal of Integrative Medicine, 2015,21(9):656-661. DOI： 10.1007/s11655-015-2306-z.

摘要

Primary osteoporosis (POP) is one of the most common diseases in the elderly people resulting in high risk of fracture and poor quality of life. In addition to the pathological changes in bone mass

most of the POP patients also suffer from Chinese medicine (CM) syndromes of Shen (Kidney) essence deficiency. Shen essences are highly related to bone. Shen essence deficiency plays an important part in the development of POP and a better diagnosis of POP could be made by combining CM syndromes with Western medicine risk factors. Treatments of POP should aim at both increasing the bone mass and relieving the syndromes of Shen essence deficiency. Clinical study confirmed that treating POP patients with Shen-tonifying herbs could increase the bone mass and relieve the CM syndromes of POP patients. Basic researches clarified the mechanism by which Shen-tonifying herbs increased bone mass in animal models. The mechanisms by which Shentonifying herbs relieve the CM syndromes are still in investigation.

Abstract

Primary osteoporosis (POP) is one of the most common diseases in the elderly people resulting in high risk of fracture and poor quality of life. In addition to the pathological changes in bone mass

关键词

Primary OsteoporosisChinese MedicinesyndromeShen (Kidney) essence deficiencyShen (Kidney)-tonifying herbs

Keywords

Primary OsteoporosisChinese MedicinesyndromeShen (Kidney) essence deficiencyShen (Kidney)-tonifying herbs

references

Siris ES, Adler R, Bilezikian J, Bolognese M, Dawson-Hughes B, Favus MJ, et al. The clinical diagnosis of osteoporosis: a position statement from the National Bone Health Alliance Working Group. Osteoporos Int 2014;25:1439–1443.

Prevention and management of osteoporosis. World Health Organization technical report series 2003;921:1–164, back cover.

Editorial Board of Osteoporosis Prevention and Treatment (China White Paper) CHPF. White paper on osteoporosis. Chin J Health Manag (Chin) 2009;3:148–154.

How W, Yan G, Liu Y, Zeng X. Analysis of bone mineral density in 1907 healthy people in Lanzhou City. Progr Modern Biomed (Chin) 2011;11:1927–1930.

Chen H, Zhou X, Washimi Y, Shoumura S. Threedimensional microstructure of the bone in a hamster model of senile osteoporosis. Bone 2008;43:494–500.

Rauner M, Sipos W, Pietschmann P. Age-dependent Wnt gene expression in bone and during the course of osteoblast differentiation. Age 2008;30:273–282.

Xie YM, Zhu YY, Ge JR, Piao HG, Yu J, Wang HM, et al. Research on basic traditional Chinese syndrome of primary osteoporosis based on clinical epidemiological investigation. World Sci Techn Modern Tradit Chin Med Mater Med (Chin) 2007;9:38–44.

Zhou XH, Chen B, Xie YM, Tian F, Liu H, Liang X. Variable selection using the optimal ROC curve: an application to a traditional Chinese medicine study on osteoporosis disease. Stat Med 2012;31:628–635.

Zhou XH, Li SL, Tian F, Cai BJ, Xie YM, Pei Y, et al. Building a disease risk model of osteoporosis based on traditional Chinese medicine symptoms and western medicine risk factors. Stat Med 2012;31:643–652.

Moe S, Drüeke T, Cunningham J, Goodman W, Martin K, Olgaard K, et al. Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 2006;69:1945–1953.

Tomat A, Gamba CA, Mandalunis P, De Grandi MC, Somaza J, Frideman S, et al. Changes in bone volume and bone resorption by olpadronate treatment in an experimental model of uremic bone disease. J Musculoskel Neur Interact 2005;5:174–181.

Zhou WJ, Yao JF, Peng XH, Shen Y, Yang H, Huang JH. Establishment of a rat model of Kidney-yang deficiency. Laborat Anim Compar Med (Chin) 2007;27:242–243.

Bian Q, Huang JH, Yang Z, Ning Y, Zhao YJ, Wang YJ, et al. Effects of active ingredients in three Kidney-tonifying Chinese herbal drugs on gene expression profile of bone marrow stromal cells from a rat model of corticosterone-induced osteoporosis. J Chin Integr Med (Chin) 2011;9:179–184.

Bhattacharyya MH, Whelton BD, Stern PH, Peterson DP. Cadmium accelerates bone loss in ovariectomized mice and fetal rat limb bones in culture. Proceed Nat Acad Sci USA 1988;85:8761–8765.

Kalu DN. The ovariectomized rat model of postmenopausal bone loss. Bone Miner 1991;15:175–191.

Tang DZ, Li CG, Cui XJ, Yang F, Yang Z, Li XF, et al. A multicenter, randomized, double-blind, and placebocontrolled study of Chinese medicine Zuogui Pill and Yougui Pill for improving bone mineral density. 36th Annual Meeting of American Society of Bone and Mineral Research. Houston, Texas, USA; 2014.

Yang Z, Bian Q, Zhao YJ, Tang DZ, Yang Z, Yang F, et al. The comparison of treatment effects and microarray analysis of Zuogui Pill and Yougui Pill on ovariectomy induced bone loss in mice. The 19th National Conference of Orthopaedics and Traumatology of Integrative Chinese Medicine. Luoyang, Henan; 2012.

Chen G, Deng C, Li YP. TGF-beta and BMP signaling in osteoblast differentiation and bone formation. Int J Biol Sci 2012;8:272–288.

Rossini M, Gatti D, Adami S. Involvement of WNT/betacatenin signaling in the treatment of osteoporosis. Calcif Tissue Int 2013;93:121–132.

Yan Y, Tang D, Chen M, Huang J, Xie R, Jonason JH, et al. Axin2 controls bone remodeling through the betacatenin-BMP signaling pathway in adult mice. J Cell Sci 2009;122:3566–3578.

Ishii T, Furuoka H, Muroi Y, Nishimura M. Inactivation of integrin-linked kinase induces aberrant tau phosphorylation via sustained activation of glycogen synthase kinase 3beta in N1E-115 neuroblastoma cells. J Biol Chem 2003;278:26970–26975.

Glass DA, Bialek P, Ahn JD, Starbuck M, Patel MS, Clevers H, et al. Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation. Dev Cell 2005;8:751–764.

Wang B, Jin H, Zhu M, Li J, Zhao L, ZHang Y, et al. Chondrocyte beta-catenin signaling regulates postnatal bone remodeling through modulation of osteoclast formation in a murine model. Arthritis Rheumatol 2014;66:107–120.

Zhao M, Qiao M, Oyajobi BO, Mundy GR, Chen D. E3 ubiquitin ligase Smurf1 mediates core-binding factor alpha1/ Runx2 degradation and plays a Specific role in osteoblast differentiation. J Biol Chem 2003;278:27939–27944.

Lan Y, Ryan RC, Zhang Z, Bullard SA, Bush JO, Maltby KM, et al. Expression of Wnt9b and activation of canonical Wnt signaling during midfacial morphogenesis in mice. Dev Dyn 2006;235:1448–1454.

Bian Q, Huang JH, Liu SF, Ning Y, Yang Z, Zhao YJ, et al. Different molecular targets of Icariin on bMSCs in CORT and OVX-rats. Front Biosci (Elite Ed) 2012;4:1224–1236.

Nian H, Ma MH, Nian SS, Xu LL. Antiosteoporotic activity of icariin in ovariectomized rats. Phytomedicine 2009;16:320–326.

Song L, Zhao J, Zhang X, Li H, Zhou Y. Icariin induces osteoblast proliferation, differentiation and mineralization through estrogen receptor-mediated ERK and JNK signal activation. Eur J Pharmacol 2013;714:15–22.

Li XF, Xu H, Zhao YJ, Tang DZ, Xu GH, Holz J, et al. Icariin augments bone formation and reverses the phenotypes of osteoprotegerin-defi cient mice through the activation of Wnt/beta-catenin-BMP signaling. Evid Based Complement Altern Med 2013;2013:652317.

Chen KM, Ge BF, Liu XY, Ma Ph, Lu MB, Bai MH, et al. Icariin inhibits the osteoclast formation induced by RANKL and macrophage-colony stimulating factor in mouse bone marrow culture. Pharmazie 2007;62:388–391.

Hsieh TP, Sheu SY, Sun JS, Chen MH. Icariin inhibits osteoclast differentiation and bone resorption by suppression of MAPKs/NF-kappaB regulated HIF-1alpha and PGE2 synthesis. Phytomedicine 2011;18:176–185.

Tang DZ, Hou W, Zhou Q, Zhang M, Holz J, Sheu TJ, et al. Osthole stimulates osteoblast differentiation and bone formation by activation of beta-catenin-BMP signaling. J Bone Miner Res 2010;25:1234–1245.

Ming LG, Wang MG, Chen KM, Zhou J, Han GQ, ZHu RQ. Effect of osthol on apoptosis and bone resorption of osteoclasts cultured in vitro. Acta Pharmac Sin 2012;47:174–179.

Zhao Y, Huai Y, Jin J, Geng M, Li JX. Quinoxaline derivative of oleanolic acid inhibits osteoclastic bone resorption and prevents ovariectomy-induced bone loss. Menopause 2011;18:690–697.

Li JF, Zhao Y, Cai MM, Li XF, Li JX. Synthesis and evaluation of a novel series of heterocyclic oleanolic acid derivatives with anti-osteoclast formation activity. Eur J Med Chem 2009;44:2796–2806.

Kim JY, Cheon YH, Oh HM, Rho MX, Erkhembaatar M, Kim MS, et al. Oleanolic acid acetate inhibits osteoclast differentiation by downregulating PLCgamma2-Ca2+-NFATc1 signaling, and suppresses bone loss in mice. Bone 2014;60:104–111.

Bian Q, Liu SF, Huang JH, Yang Z, Tang DZ, Zhou Q, et al. Oleanolic acid exerts an osteoprotective effect in ovariectomy-induced osteoporotic rats and stimulates the osteoblastic differentiation of bone mesenchymal stem cells in vitro. Menopause 2012;19:225–233.

Yang Z, Huang JH, Liu SF, Zhao YJ, Shen ZY, Wang YJ, et al. The osteoprotective effect of psoralen in ovariectomyinduced osteoporotic rats via stimulating the osteoblastic differentiation from bone mesenchymal stem cells. Menopause 2012;19:1156–1164.

Tang DZ, Yang F, Yang Z, Huang J, Shi Q, Chen D, et al. Psoralen stimulates osteoblast differentiation through activation of BMP signaling. Biochem Biophys Res Commun 2011;405:256–261.

Wu C, Sun Z, Ye Y, Han X, Song X, Liu S. Psoralen inhibits bone metastasis of breast cancer in mice. Fitoterapia 2013;91:205–210.

FULL TEXT LINK

More>

浏览量

162

Downloads

CSCD

文章被引用时，请邮件提醒。

Submit

工具集

关联资源

Key symptoms selection for two major syndromes diagnosis of Chinese medicine in chronic hepatitis B

Effect of Yangxinkang Tablets (养心康片) on chronic heart failure: A multi-center randomized double-blind placebo-controlled trial

Future view and development of immunology: Exploring the immunology based on Chinese medicine and culture

Cost-effectiveness analysis of combined Chinese medicine and Western medicine for ischemic stroke patients